Clinical Trial Update: A Phase 4 Study to Assess the Impact of Patient Support Program on Health Related Quality of Life and Adherence in Subjects With Relapsing-Remitting Multiple Sclerosis Administered Rebif® With the RebiSmart™ Device [Phase 4]

View source ↗

Summary

A Phase 4 study evaluating whether a patient support program improves health-related quality of life and adherence in people with relapsing-remitting multiple s…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Relapsing-remitting Multiple Sclerosis

Drugs mentioned

• Rebif (interferon beta-1a)

Snippet

Sponsor: Merck KGaA, Darmstadt, Germany | Conditions: Multiple Sclerosis, Relapsing-Remitting | Phase 4 | Status: COMPLETED | Results posted: 2017-07-12